Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04906642
Other study ID # CSP-018
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date May 4, 2021
Est. completion date September 1, 2023

Study information

Verified date November 2023
Source Next Science TM
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective, randomized, controlled, double-blinded clinical feasibility study of subjects that are being treated for Gustilo and Anderson Type II or IIIA or IIIB Tibial Fractures


Description:

This is a prospective, controlled, double-arm, double-blinded, randomized clinical study of 30 subjects that are undergoing single stage surgical repair of Type II or IIIA or IIIB tibial fractures. Institutional Review Board (IRB) approval is required before the site can begin enrolling patients. Additionally, protocol amendments need to be approved by the IRB prior to starting any changes or procedures stemming from the amended protocol. Potentially eligible patients will be offered study enrollment and all subjects are required to participate in the informed consent process and sign the most recent IRB-approved written informed consent document prior to being enrolled in the study. If all the study inclusion/exclusion criteria are met, patients will be presented with the option to participate in the study and informed consent procedures will be carried out, in compliance with currently applicable subjects' rights and safety regulations. Reconsenting procedures for cases of protocol amendments will be performed in compliance with the IRB. Patients who present for open tibial fracture repair surgery will have a pre-op medical evaluation prior to being screened against the protocol's inclusion/exclusion criteria. If criteria are met, patients will be presented with the option to participate in the study, and informed consent procedures will be carried out, in compliance with currently applicable participants' rights and safety regulations. At the time of surgery, participants determined to require surgical repair of a Type IIIC tibial fracture will be excluded. Patients who continue to be eligible meeting inclusion/exclusion criteria at the time of surgery will be randomized to one of the two treatment arms: SOC with Saline or SOC plus Next Science treatment. The treatment assignment will be predetermined by a randomization plan within Castor Electronic Data Capture (EDC) system. Although, paper source documents will be used to obtain subject data, randomization will be primarily through the EDC system. As a back-up, should the EDC system be unavailable at that time, randomization will occur using a sealed envelope system. The following must have occurred prior to determining treatment assignment: - Screening - Participant must meet all eligibility requirements - Informed Consent must be signed - Continued Eligibility screening - Randomization must occur* - Randomization occurs prior to surgery based on Exclusion #8. If the index fractures are bilateral, right leg will be randomized while the other leg will be assigned to the opposite treatment arm to prevent dosing of identical products on one subject. Once surgical evaluation occurs if the index fracture is determined to be Type II, IIIA or IIIB (that does not require referral to another surgical service [vascular, plastic surgery] ) then the subject will continue to dosing. If the index fracture(s) must receive additional surgical referrals they will not be dosed, considered a screen failure, and exited from the study. If the patient fails to meet continued eligibility: - Screen Failure and - Study Exit forms must be completed. Accurate recording of the information per section 9.3 is critical for the traceability of treatment and product to a participant. The duration of each subjects' participation once eligible and approved to start treatment, will start from Day 1 (first index surgery) and end at the Day 90 Visit. On-site visits will be carried out at Screening/Enrollment; Day of Surgery; Day of Discharge; and Days 14, 30, and 90; consisting of safety, bone healing (via X-ray findings), bioburden assessment, and surgical site infection assessment questions. The key parameters of the study include bioburden and surgical site infection assessment, re-admission assessment, serious adverse events, and healthcare cost impact. Bacterial identification and quantification will be evaluated via two methods: PCR/NGS (according to this protocol) and microbiology/pathology (according to site SOC). PCR/NGS swabs will be taken after fracture fixation inside the wound and then around the closed surgical incision: - After fracture fixation (deep tissue): Swabs will be performed right after fracture fixation, before blinded rinse, and then immediately after blinded irrigation. The swabs will be performed on the entire wound base and around the fixation device. The time of collection for each swab must be specific (hour and minute) and recorded on the specimen label and requisition form. - After closed surgical incision (superficial): After final closure, swabs will be taken within the 1-2cm perimeter surrounding the entire incision. This will be repeated on the day of discharge. The time of collection for each swab must be specific (hour and minute) and recorded on the specimen label and requisition form.


Recruitment information / eligibility

Status Terminated
Enrollment 17
Est. completion date September 1, 2023
Est. primary completion date July 5, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Male or female 18 to 65 years old 2. Scheduled to undergo surgery to repair open tibial fracture 3. Willing and able to comply with all study procedures and be available for the duration of the study 4. Provide signed and dated informed consent or obtain consent from legally authorized representative 5. Not be pregnant, planning to become pregnant, or nursing female subjects. Exclusion Criteria: 1. Unable to provide signed and dated informed consent or unable to obtain consent from a legally authorized representative 2. Unable or unwilling to comply with all study-related procedures 3. Known history of allergic reaction to any of the study products or its components, including any products used for standard of care (such as dressings or any coverings) 4. Subject has known history of contraindications to general anesthesia 5. Subject with any underlying condition or state that, in the investigator's opinion, will make them too critically ill to complete 30 and/or 90 day follow ups 6. Pregnant, planning to become pregnant, or nursing female subjects. 7. Any subject positive for Covid-19 virus at time of surgical screening 8. Tibial plateau, pilon, or Gustilo-Anderson type IIIc fractures and any fracture that will require referral to another surgical service will be excluded from this study 9. Any patient who will require ongoing use of NPWT after hospital discharge will be excluded from the study. 10. Subjects have evidence of prolonged QT segment, per EKG. 11. Subjects from a vulnerable population, in accordance with 45 CFR 46 Subparts B, C, and D

Study Design


Intervention

Device:
Next Science
Solution is a clear, colorless, aqueous solution that is used to remove debris, including microorganisms, from wounds via hydrodynamic shear across the wound. This aids in the removal of foreign material such as, microorganisms, dirt, and debris.
Other:
Standard of Care
Normal Saline will be used in place of Next Science for irrigation

Locations

Country Name City State
United States University of Alabama at Birmingham Birmingham Alabama
United States Piedmont Healthcare Columbus Georgia

Sponsors (3)

Lead Sponsor Collaborator
Next Science TM Hughston Clinic, Piedmont Healthcare

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Surgical Site Infection Proportion of subjects that develop a surgical site infection (superficial, deep, or organ space) from surgery to post-op Day 90 for the Next Science Group compared to the Control group. 90 days
Secondary Superficial Bioburden Mean change in bioburden around the closed incision, as evaluated via PCR/NGS, from baseline to Day of Discharge for the Next Science Group compared to the Control group. 90 days
Secondary Deep Bioburden Mean change in bioburden from the deep tissue immediately after fixation around the fixation site, as evaluated via PCR/NGS, before and after use of the blinded product for the Next Science Group compared to the Control group 1 day
See also
  Status Clinical Trial Phase
Completed NCT05529173 - Povidone-Iodine for Nasal Decolonization Phase 4
Recruiting NCT03295955 - Comparing Efficacy of Postoperative Oral Antibiotic Use in Trans-Oral Thyroidectomy N/A
Not yet recruiting NCT05276687 - Efficacy of Diluted Betadine vs Antibiotic Installation Before Surgical Wound Closure in Prevention of Post Cardiac Surgery Wound Infection Phase 4
Completed NCT02776774 - Topical Antibiotic Treatment for Spine Surgical Site Infection
Terminated NCT00386477 - Vaginal Cleansing at Cesarean Delivery to Reduce Infection: A Randomized, Controlled Trial N/A
Not yet recruiting NCT03872544 - Short Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
Recruiting NCT05077592 - Addition of Pre-wound Closure Povidone Iodine Wash Versus Direct Wound Closure Effect on Surgical Site Infections Phase 4
Completed NCT03148067 - Incidence and Risk Factors for Surgical Site Infection After Intramedullary Nailing of Femoral and Tibial Fractures
Enrolling by invitation NCT03880188 - Long Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
Completed NCT01890720 - Incisional Negative Pressure Wound Therapy for Prevention of Postoperative Infections Following Caesarean Section N/A
Recruiting NCT06319235 - Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG® Phase 1/Phase 2
Completed NCT02919410 - Bacterial Colonization With and Without Iodophor-impregnated Adhesive Drapes in Hip Surgery: a Prospective, Randomized Trial N/A
Completed NCT02020018 - Negative Pressure Wound Therapy for Prevention of Poststernotomy Infection N/A
Completed NCT01741649 - Clorhexidine Versus Povidone for the Prevention of Surgical Site Infection After Cesarean Section N/A
Not yet recruiting NCT01457859 - Effectiveness of Triclosan Coated Sutures in Preventing Leg Wound Infection After Coronary Artery Bypass Surgery Phase 4
Completed NCT01340534 - Supplemental Perioperative Oxygen to Reduce the Incidence of Post-cesarean Wound Infection Phase 3
Completed NCT03365219 - Alexis O-Ring Wound Retractor for the Prevention of Post-cesarean Surgical Site Infections N/A
Completed NCT01026259 - Local Warming of Surgical Incisions Phase 3
Completed NCT03574090 - Study the Efficacy of Topical Antibiotherapy in the Prophylaxis of Incisional Surgical Infection in Colorectal Surgery Phase 4
Completed NCT03199911 - Topical Antibiotic Prophylaxis for Eyelids Phase 4